[1]
|
Farquhar, J.W. and Claireaux, A.E. (1952) Familial Haemophagocytic Reticulosis. Archives of Disease in Childhood, 27, 519-525. https://doi.org/10.1136/adc.27.136.519
|
[2]
|
Ishii, E. (2016) Hemophagocytic Lymphohistiocytosis in Children: Pathogenesis and Treatment. Frontiers in Pediatrics, 4, Article 202648. https://doi.org/10.3389/fped.2016.00047
|
[3]
|
Yao, S., Wang, Y., Sun, Y., et al. (2021) Epidemiological Investigation of Hemophagocytic Lymphohistiocytosis in China. Orphanet Journal of Rare Diseases, 16, Article No. 342. https://doi.org/10.1186/s13023-021-01976-1
|
[4]
|
Chang, Y., Cui, M., Fu, X., et al. (2018) Lymphoma Associated Hemophagocytic Syndrome: Asingle-Center Retrospective Study. Oncology Letters, 16, 1275-1284. https://doi.org/10.3892/ol.2018.8783
|
[5]
|
Li, B., Guo, J., Li, T., et al. (2021) Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 21, E198-E205. https://doi.org/10.1016/S2152-2650(21)02106-6
|
[6]
|
Henter, J.I., Horne, A., Aric6, M., et al. (2007) HL-2004: Diagnostic and Therapeutic Guidelines for Hemophagocytic Lymphohistiocytosis. Pediatric Blood & Cancer, 48, 124-131. https://doi.org/10.1002/pbc.21039
|
[7]
|
王昭, 石远凯. 淋巴瘤相关噬血细胞综合征诊治中国专家共识(2022年版) [J]. 中华医学杂志, 2022, 102(24): 1794-1801.
|
[8]
|
Xie, M., Li, L., Zhu, L., et al. (2018) An Effective Diagnostic Index for Lymphoma-Associated Hemophagocytic Syndrome. QJM: An International Journal of Medicine, 111, 541-547. https://doi.org/10.1093/qjmed/hcy103
|
[9]
|
Chen, C.L., Li, M.J., Liu, Y.N., et al.(2019) Expression and Its Implications of Th1/Th2 Cytokines and Lymphocyte Subsets in Adult Patients with Lymphoma-Associated Hemophagocytic Lymphohistiocytosis. Chinese Journal of Hematology, 40, 777-779.
|
[10]
|
张文丽, 许蕾, 张倩, 等. 流式细胞分析对以噬血细胞综合征为首发症状的非霍奇金淋巴瘤的诊断价值分析[J]. 中华内科杂志, 2020, 59(12): 976-981.
|
[11]
|
Yuan, S., Wang, Y., Luo, H., et al. (2020) Serum Soluble VSIG4 as a Surrogate Marker for the Diagnosis of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis. British Journal of Haematology, 189, 72-83. https://doi.org/10.1111/bjh.16299
|
[12]
|
Hayden, A., Lin, M., Park, S., et al. (2017) Soluble Interleukin-2 Receptor Is a Sensitive Diagnostic Test in Adult HLH. Blood Advances, 1, 2529-2534. https://doi.org/10.1182/bloodadvances.2017012310
|
[13]
|
Zoref-Lorenz, A., Murakami, J., Hofstetter, L., et al. (2022) An Improved Index for Diagnosis and Mortality Prediction in Malignancy-Associated Hemophagocytic Lymphohistiocytosis. Blood, 139, 1098-1110. https://doi.org/10.1182/blood.2021012764
|
[14]
|
Zou, H., He, L., Hue, Z., et al. (2023) Serum SCD25/Ferritin Ratio Combined with MCP-1 Is a Valid Predictor for Identifying LAHS with HLH as the First Manifestation. Journal of Cancer Research and Clinical Oncology, 149, 8521-8533. https://doi.org/10.1007/s00432-023-04781-4
|
[15]
|
Ren, Q., Chan, K.W., Huang, H., et al. (2020) Platelet-Derived α-Granules Are Associated with Inflammation in Patients with NK/T-Cell Lymphoma-Associated Hemophagocytic Syndrome. Cytokine, 126, Article ID: 154878. https://doi.org/10.1016/j.cyto.2019.154878
|
[16]
|
He, Y.X., Gao, Y., Wang, X., et al. (2023) The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis. Blood, 142, 6218. https://doi.org/10.1182/blood-2023-186496
|
[17]
|
Lin, C.H., Shih, Y.H., Chen, T.C., et al. (2021) A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve? Journal of Clinical Medicine, 10, Article 5114. https://doi.org/10.3390/jcm10215114
|
[18]
|
Li, N., Jiang, M., Wu, W.C., et al. (2022) Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective Study from a Single Center. Hematology, 27, 909-916. https://doi.org/10.1080/16078454.2022.2113600
|
[19]
|
郑良达, 江文华,王娴婷, 等. P53和C-Myc表达对弥漫大B细胞淋巴瘤相关噬血细胞综合征的预后影响[J]. 中国现代医生, 2023, 61(25): 5-8, 13.
|
[20]
|
Cheng, W., Duan, L., Xu, J., et al.(2023) Prognostic Value of the Albumin-Bilirubin Score in Patients with Non-Hodgkin Lymphoma-Associated Hemophagocytic Lymphohistiocytosis. Frontiers in Immunology, 14, Article 1162320. https://doi.org/10.3389/fimmu.2023.1162320
|
[21]
|
Janka, G.E. and Lehmberg, K. (2014) Hemophagocytic Syndromes—An Update. Blood Advances, 28, 135-142. https://doi.org/10.1016/j.blre.2014.03.002
|
[22]
|
Bergsten, E., Horne, A., Aricó, M., et al. (2017) Confirmed Efficacy of Etoposide and Dexamethasone in HLH Treatment: Long-Term Results of the Cooperative HLH-2004 Study. Blood, 130, 2728-2738. https://doi.org/10.1182/blood-2017-06-788349
|
[23]
|
Johnson, T.S., Terrell, C.E., Millen, S.H., et al.(2014) Etoposide Selectively Ablates Activated Tcells to Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis. Journal of Immunology, 192, 84-91. https://doi.org/10.4049/jimmunol.1302282
|
[24]
|
Ellin, F., Landström, J., Jerkeman, M., et al. (2014) Real-World Data on Prognostic Factors and Treatment in Peripheral T-Cell Lymphomas: A Study from the Swedish Lymphoma Registry. Blood, 124, 1570-1577. https://doi.org/10.1182/blood-2014-04-573089
|
[25]
|
Song, Y., Wang, J., Wang, Y., et al. (2021) Requirement for Containing Etoposide in the Initial Treatment of Lymphoma Associated Hemophagocytic Lymphohistiocytosis. Cancer Biology & Therapy, 22, 598-606. https://doi.org/10.1080/15384047.2021.1996139
|
[26]
|
Meng, G., Wang, Y., Wang, J. and Wang, Z. (2021) the DEP Regimen Is Superior to the HLH-1994 Regimen as First-Line Therapy for Lymphoma-Associated Haemophagocytic Lymphohistiocytosis. Journal of Leukemia and Lymphoma, 62, 854-860. https://doi.org/10.1080/10428194.2020.1849671
|
[27]
|
Pi, Y., Wang, J., Zhou, H., et al. (2023) Modified DEP Regimen as Induction Therapy for Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Prospective, Multicenter Study. Journal of Cancer Research and Clinical Oncology, 149, 3033-3041. https://doi.org/10.1007/s00432-022-04157-0
|
[28]
|
Das, R., Guan, P., Sprague, L., et al. (2016) Janus Kinase Inhibition Lessens Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis. Blood, 127, 1666-1675. https://doi.org/10.1182/blood-2015-12-684399
|
[29]
|
Zhou, L., Liu, Y., Wen, Z., et al. (2020) Ruxolitinib Combined with Doxorubicin, Etoposide, and Dexamethasone for the Treatment of the Lymphoma-Associated Hemophagocytic Syndrome. Journal of Cancer Research and Clinical Oncology, 146, 3063-3074. https://doi.org/10.1007/s00432-020-03301-y
|
[30]
|
Zhou, D., Huang, X., Xie, M., et al. (2023) Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single-Center Pilot Trial. American Journal of Hematology, 98, E106-E109. https://doi.org/10.1002/ajh.26877
|
[31]
|
Meyer, L.K., Verbist, K.C., Albeituni, S., et al. (2020) JAK/STAT Pathway Inhibition Sensitizes CD8 T Cells to Dexamethasone-Induced Apoptosis in Hyperinflammation. Blood, 136, 657-668. https://doi.org/10.1182/blood.2020006075
|
[32]
|
Stalder, G., Suffiotti, M., Segot, A., et al. (2023) Response-Adjusted Regimen Combining Ruxolitinib, Etoposide and Dexamethasone (AdRED) in Adult Patients with Acute Myeloid Leukemia-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center Pilot Trial. Haematologica, 108, 234-239. https://doi.org/10.3324/haematol.2022.281221
|
[33]
|
Wang, H., Fu, B.B., Gale, R.P., et al. (2021) NK-/T-Cell Lymphomas. Leukemia, 35, 2460-2468. https://doi.org/10.1038/s41375-021-01313-2
|
[34]
|
He, Y., Gao, Y., Ping, L., et al. (2023) The Emerging Role of Anti-PD-1 Antibody-Based Regimens in the Treatment of Extranodal NK/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis. Journal of Cancer Research and Clinical Oncology, 149, 2017-2027. https://doi.org/10.1007/s00432-022-04147-2
|
[35]
|
Xu, Q.Y., Yang, H.Y., Li, M.W., et al. (2022) Sintilimab Combined with Chidamide in the Treatment of Extranodal Nature Killer/T-Cell Lymphoma with Secondary Hemophagocytic Lymphohistiocytosis: Two Case Reports and Literature Review. Medicine, 101, e30731. https://doi.org/10.1097/MD.0000000000030731
|
[36]
|
Faguer, S., Vergez, F., Peres, M., et al. (2016) Tocilizumab Added to Conventional Therapy Reverses Both the Cytokine Profile and CD8 Granzyme T-Cells/NK Cells Expansion in Refractory Hemophagocytic Lymphohistiocytosis. Journal of Hematology & Oncology, 34, 55-57. https://doi.org/10.1002/hon.2174
|
[37]
|
Dufranc, E., Del Bello, A., Belliere, J., et al. (2020) IL6-R Blocking with Tocilizumab in Critically Ill Patients with Hemophagocytic Syndrome. Journal of Critical Care, 24, Article No. 166. https://doi.org/10.1186/s13054-020-02878-7
|
[38]
|
Kim, J.Y., Kim, M., Park, J.K., et al. (2022) Limited Efficacy of Tocilizumab in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: A Retrospective Cohort Study. Orphanet Journal of Rare Diseases, 17, Article No. 363. https://doi.org/10.1186/s13023-022-02516-1
|